WO1989000164A1 - Proteines membranaires specifiques des chondroblastes et procede de diagnostic et de controle de reactions auto-immunitaires contre des chondroblastes - Google Patents

Proteines membranaires specifiques des chondroblastes et procede de diagnostic et de controle de reactions auto-immunitaires contre des chondroblastes Download PDF

Info

Publication number
WO1989000164A1
WO1989000164A1 PCT/EP1988/000572 EP8800572W WO8900164A1 WO 1989000164 A1 WO1989000164 A1 WO 1989000164A1 EP 8800572 W EP8800572 W EP 8800572W WO 8900164 A1 WO8900164 A1 WO 8900164A1
Authority
WO
WIPO (PCT)
Prior art keywords
cartilage
specific membrane
cartilage cell
protein according
cell
Prior art date
Application number
PCT/EP1988/000572
Other languages
German (de)
English (en)
Inventor
Klaus Von Der Mark
Jürgen MOLLENHAUER
Original Assignee
Max-Planck-Gesellschaft Zur Förderung Der Wissensc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Planck-Gesellschaft Zur Förderung Der Wissensc filed Critical Max-Planck-Gesellschaft Zur Förderung Der Wissensc
Publication of WO1989000164A1 publication Critical patent/WO1989000164A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Definitions

  • the invention relates to the provision of cartilage cell-specific membrane proteins for the detection of immune reactions with autoantibodies.
  • the invention also relates to methods for diagnosing and monitoring the course of autoimmune reactions against cartilage cells.
  • the group of these diseases includes, for example, chronic polyarthritis, osteoarthritis or gout. These are some of the most common civilization diseases. They are caused by improper nutrition, occupational damage to posture, but also by intensive sporting activities.
  • components of the extracellular matrix of the cartilage such as collagen type II (NA Andriopoulos et al. (1976), Arthritis Rheum. 19, 613; DC), are the targets of the cellular and humural autoimmune reaction which occur as a concomitant symptom of the diseases mentioned Haynes et al., (1985), J. Rheumatol. 13, 358), histocompatibility antigens (GR Burmester et al.
  • the invention is therefore based on the object of providing effective test antigens which permit diagnosis and monitoring of the diseases mentioned, in particular in humans.
  • Another object of the invention is to provide a method for diagnosing and monitoring the diseases mentioned, in particular those which occur in humans.
  • the invention thus relates to cartilage cell-specific membrane proteins which have an immunoreactivity with autoantibodies and are obtainable from
  • the invention also relates to cartilage cell-specific membrane proteins which have immunoreactivity with autoantibodies and are obtainable from
  • cartilage cell-specific membrane proteins by electrophoresis of the membrane vehicle in an SDS polyacrylamide gel and electrophoretic elution of the proteins from the SDS polyacrylamide gel.
  • Specific examples of cartilage cell-specific membrane proteins of the invention are by relative molecular weights (M) of 155,000, 116,000, 78,000, 76,000, 66,000,
  • Another object of the invention is a method for the diagnosis and course control of autoimmune reactions against cartilage cells, which is characterized in that a mixture of cartilage cell-specific membrane components is used as test antigen in an immunological detection method for the detection of autoantibodies.
  • the expression “cartilage cell-specific membrane component” denotes components of the covering of cartilage cells of vertebrates that do not occur in the nearer or further extracellular cartilage matrix and that are not histocompatibility antigens.
  • proteins of the shell of cartilage cells of vertebrates which do not occur in the nearer or further extracellular cartilage matrix and which are not histocompatibility antigens are referred to as "cartilage cell-specific membrane proteins”.
  • cartilage cell-specific membrane components of human cells be used as a test system for the antibodies from human blood, but heterologous materials can also be used, for example cartilage cell-specific membrane proteins from chickens and rats.
  • the main advantage of using these proteins is that they are always available in sufficient quantities. Therefore, the cartilage cell-specific membrane components and membrane 11 proteins around those found in human hyaline cartilage,
  • the cartilage cell-specific membrane components and membrane proteins of the chicken are particularly preferred.
  • the expression" laboratory or farm animals “used in the description of the present invention refers to animals such as rats, mice, rabbits, guinea pigs, cattle, pigs, rCC Denoted sheep, goat, horse or chicken.
  • cartilage cell itself the main goal.
  • the first contact of the immune system with the cartilage cell takes place via its outer membrane.
  • the constituents of the membrane are thus causally at the top of the reaction cascade in auto-sensitization.
  • the experimental observations according to the invention open up new possibilities for the diagnosis and monitoring of the course of acute and chronic diseases of the cartilage, in particular of chronic polyarthritis " and osteoarthrosis.
  • early diagnosis of arthrotic processes is possible, which is already possible with slight, for example sports-related, damage of the joints occur and are accompanied by significant autoantibody titers.
  • the methods according to the invention now make it possible to monitor the course of rheumatoid diseases. Suitable therapeutic measures can thus be selected and controlled. In particular, the validity of medicamentous treatment, for example with chondroprotectives, can be assessed better than hitherto.
  • the studies carried out according to the invention relate on the one hand to the qualitative detection of autoimmune aggression by circulating antibodies of the patients with the associated specific antigens and on the other hand to the quantitative check whether the titer of these antibodies is correlated with the extent of the disease. ⁇ -
  • Fig. 2 shows the inhibition of autoantibody activity of osteoarthritis with cartilage cell plasma membranes or a
  • intersection values can be used as a measure of the immunoreactivity. These values are shown collectively in FIG. 4.
  • 35 4 shows the cumulative recording of the extrapolation values from the titration curves of the ELISA (see FIG. 3).
  • Pancreatic tumor cell membranes (C) as antigens on the solid phase are pancreatic tumor cell membranes (C) as antigens on the solid phase.
  • Solid phase 0.005 mg cartilage cell membrane protein was used per 96 well of the microtiter plate from juvenile human cartilage.
  • Chicken cartilage cell membrane proteins served as antigen.
  • A blots;
  • B Coomassie blue - colored 5-15% SDS-polyacrylamide gradient gel of the membrane proteins, which served as a template for the blot.
  • Column "Mr” relative molar mass of the additionally applied molar mass marker proteins, expressed in kilodaltons.
  • Goat anti-human polyvalent immunoglobulin peroxidase (A 8400), rabbit anti-human serum (H 3383) and 4-chloro-naphtol (C 8890) are obtained from Sigma-Chemie, Kunststoff; Goat anti-rabbit immunoglobulin peroxidase (8940) from Research Plus Laboratories, Denville, NJ, USA; Nitrocellulose paper (0.45 ⁇ m. Pore size) from Sartorius GmbH, Göttinqen; 2,2 '.Azino-di-3-ethylbenzthiazoline sulfonate (6) (ABTS, 102956) from Boehrinqer, Mannheim. All other chemicals were purchased in p.A. quality from Merck, Darmstadt.
  • Plasma membranes from cell culture human foreskin fibroblasts, ductal pancreatic adenocarcinoma: The cells are scraped off the culture vessel and in 8.5% (w / w) sucrose, 0.01 M Tris HC1, pH 7.5, 1 mM protease inhibitors (N -Ethylmalein- imid, phenylmethylsulfonic acid) transferred.
  • the further preparation is carried out according to Cates and Holland (1978), 40%, 17% and 8.5% sucrose (w / w), the latter with the sample, being present in the sucrose gradient from bottom to top.
  • the plasma membranes are concentrated on the 40% / 17% boundary layer. After dialysis against phosphate buffered saline (PBS) + protease inhibitors. the membranes are portioned and frozen.
  • PBS phosphate buffered saline
  • Membranes of human, rat and chicken cartilage, human articular cartilage from surgical material, rat or chicken breast cartilage are homogenized with an Ultraturrax in 8.5% sucrose buffer as described above.
  • the crushed solid becomes by centrifugation at 1500 g, 15 min., 4 ° C
  • Immunodot assays of 0.002 mg membrane protein are drawn onto the nitrocellulose per well of the incubation chamber (biorad). The paper is then saturated with 3% skim milk powder in PBS for 2 hours. The sera to be examined are titrated in steps of 2 or 3 in PBS / milk powder and incubated on the plate for 2 hours. After washing five times with PBS, the reaction is carried out with the detection antibodies. This can be indirect or direct, the indirect one being approximately 10 times more sensitive.
  • the paper is incubated with rabbit anti-human IgH diluted 1: 500 (PBS / milk powder) for 2 hours, washed five times with PBS and a further 2 hours with goat anti-rabbit diluted 1: 200 Incubated peroxidase.
  • the detection reaction is carried out with chloronaphtol (dilute stock solution (10 mg chloronaphtol in 10 ml methanol) 1: 5 in PBS, pH 6.5, and add 100 ⁇ l HO- to 100 ml).
  • the reaction should take place in the dark, since the resulting dye is sensitive to light.
  • the titration of the sera can now be read directly from the blue color or measured in a reflection photometer.
  • ⁇ m th case of the direct detection method is by incubation with the Patien ⁇ tenseren directly goat anti-human-peroxidase (1: 500) was applied otherwise as described above.
  • 0.002 mg membrane protein in 100 ⁇ l HO deion are used. suspended, applied per hole and adsorbed onto the plate by freeze-drying. The plate is now saturated with skimmed milk powder (3%, PBS) for 2 hours and can be used as described above for the immunodot.
  • PBS skimmed milk powder
  • the membrane proteins are separated in SDS gel electrophoresis (according to UK Laemmli, Nature 227 (1970), p. 680) in a 5-15% polyacrylamide gel after reduction with dithiothreitol. Typically 0.1 mg membrane protein is applied per gel lane.
  • a reference gel strip is stained with Coomassie blue, the rest is transferred electrophoretically to a mitrocellulose paper overnight at room temperature.
  • the electrophoresis buffer contains 0.1% SDS. After the transfer has been completed, the paper is saturated with milk powder / PBS and incubated with the individual patient sera in suitable dilution (PBS / milk powder solution) overnight at 4 ° C. Bound immune globulins be makes above 'for the immunodot beschrie ⁇ ben in the direct or indirect detection methods visible ge, wherein the individual incubation with neighboring facing antibodies take place overnight at 4 ° C.
  • the inhibition ELISA further underlines the reduced immunoreactivity of extracellular matrix proteins compared to the plasma membranes (FIG. 2).
  • the antibody activity in the patient's serum can be completely inhibited with plasma membranes, while even by combining all types of collagen of the cartilage only about 30% inhibition of the sera can be achieved.
  • 3 and 4 show the titration of patient and control sera in the ELISA on chicken cartilage membrane as an antigen.
  • 5 shows the cross-reactivity of some sera against human fibroblast membranes and against membranes from a pancreatic adenocarcinoma cell line. The reaction against cartilage cell membranes in the case of sera from polyarthritics as a whole, at least in some cases with arthrotics, is clearly above the values of the control groups. On the other hand, there is only a non-specific reactivity in the control area on the fibroblast and tumor cell membranes. Irrespective of these experiments, the ELISA titrations of osteoarthritis patient sera and controls shown in FIG. 5 were carried out with juvenile human cartilage as the antigen.
  • the decisive factor for the quality of the antibody detection system is its discriminatory property. In the present case that only a defined number of proteins from the whole of the cartilage cell specific membrane protein 0 m is expected to respond it the patient sera.
  • FIGS. 6 and 7 show immunoblots with some sera from patients with osteoarthritis (FIG. 6) or chronic polyarthriti (FIG. 7).
  • 8 shows a control immunobiot with combined sera from osteoarthritis and chronic polyarthritis patients and with human fibroblast and pancreatic tumor cell membranes as the 'antigen.
  • the defined areas in the blots in FIGS. 6 and 7 and their absence in FIG. 8 are to be noted. This is a strong indication of the cartilage cell specificity of the immune reaction.
  • the recognized cartilage cell antigens are listed in Table I according to their relative molecular weight. Thereby osteoarthritis and chronic polyarthritis are compared directly. It can be seen that the antigens are essentially identical. This is a further indication of the high specificity of the proven immune response.
  • Example 3 a statement should also be made here about the discriminatory properties of the detection system, here of the ELISA. With chicken cartilage cell membranes as detection antigen, it is checked to what extent different types of membrane in suspension can inhibit the reactivity of the patient sera.
  • Table II shows an overview of the results obtained. It can be seen that membranes from chicken cartilage can inhibit the activity of polyarthritic sera, so that the residual activity corresponds to the background reaction of the control sera. Membranes from rat and human cartilage cells inhibit similarly well. When the membranes are treated with enzymes that digest the extracellular matrix from the surface of the membrane vesicles (collagenase, hyaluronic acid, chondroitinase ABC), the inhibitory capacity is also retained. Participation of collagen and proteoglycans in a (possibly unspecific secondary) immune reaction can therefore be excluded. In contrast, the non-specific protease trypsin completely destroys the cell surface proteins and thereby eliminates any inhibitory activity of the membranes treated in this way.
  • enzymes that digest the extracellular matrix from the surface of the membrane vesicles collagenase, hyaluronic acid, chondroitinase ABC
  • the inhibitory capacity is also retained. Participation of collagen and proteoglycans in
  • the digested peptides released by trypsin can also no longer bind to the body.
  • these membrane types are also not able to block the immune reaction of the patient sera.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des protéines membranaires spécifiques des chondroblastes présentent une réactivité immunitaire à auto-anticorps et peuvent être obtenues par homogénéisation de tissus cartilagineux, par isolation des vésicules membranaires contenues dans l'homogénéisat par séparation et récupération des protéines contenues dans les vésicules. Ces protéines membranaires spécifiques des chondroblastes sont utiles pour diagnostiquer et contrôler des réactions auto-immunitaires contre des chondroblastes.
PCT/EP1988/000572 1987-07-01 1988-06-30 Proteines membranaires specifiques des chondroblastes et procede de diagnostic et de controle de reactions auto-immunitaires contre des chondroblastes WO1989000164A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3721790.9 1987-07-01
DE19873721790 DE3721790C2 (de) 1987-07-01 1987-07-01 Knorpelzellspezifische Membranproteine und Bestecke zur Diagnose und Verlaufskontrolle von Autoimmunreaktionen gegen Knorpelzellen

Publications (1)

Publication Number Publication Date
WO1989000164A1 true WO1989000164A1 (fr) 1989-01-12

Family

ID=6330712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1988/000572 WO1989000164A1 (fr) 1987-07-01 1988-06-30 Proteines membranaires specifiques des chondroblastes et procede de diagnostic et de controle de reactions auto-immunitaires contre des chondroblastes

Country Status (2)

Country Link
DE (1) DE3721790C2 (fr)
WO (1) WO1989000164A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155714A (en) * 1988-02-18 1992-10-13 Sony Corporation Interleaving method for interleaved magneto-optic recording of a track
WO2000017359A1 (fr) * 1998-09-24 2000-03-30 Genzyme Corporation Nouveaux polynucleotides associes au cartilage, polypeptides codes par ces derniers et utilisations associees

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681600B1 (fr) * 1991-09-24 1995-05-19 Clonatec Sa Antigenes specifiquement reconnus par des anticorps specifiques de la polyarthrite rhumatouide, leurs proteines constitutives, leur preparation et leurs applications.
EP0511116B1 (fr) * 1991-04-26 2004-06-16 Clonatec S.A. Antigènes reconnus par des anticorps de la polyarthrite rhumatoide, leur préparation et leurs applications
US10877033B2 (en) 2013-06-18 2020-12-29 Oxford University Innovation Limited Method of detecting the presence or absence of autoantibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145681A1 (fr) * 1983-09-09 1985-06-19 Pharmacia Ab Méthode pour déterminer des changements dans des cartilages
EP0205337A2 (fr) * 1985-06-11 1986-12-17 COLLAGEN CORPORATION (a Delaware corporation) Antigènes de chondrocytes et anticorps monoclonaux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145681A1 (fr) * 1983-09-09 1985-06-19 Pharmacia Ab Méthode pour déterminer des changements dans des cartilages
EP0205337A2 (fr) * 1985-06-11 1986-12-17 COLLAGEN CORPORATION (a Delaware corporation) Antigènes de chondrocytes et anticorps monoclonaux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of biological Chemistry, Band 263, Nr. 12, 25. April 1988, (US), P. Fernandez: "The structure of anchorin CII, a collagen binding protein isolated from chondrocyte membrane", Seiten 5921-5925, *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155714A (en) * 1988-02-18 1992-10-13 Sony Corporation Interleaving method for interleaved magneto-optic recording of a track
WO2000017359A1 (fr) * 1998-09-24 2000-03-30 Genzyme Corporation Nouveaux polynucleotides associes au cartilage, polypeptides codes par ces derniers et utilisations associees

Also Published As

Publication number Publication date
DE3721790A1 (de) 1989-01-12
DE3721790C2 (de) 1996-02-22

Similar Documents

Publication Publication Date Title
DE102005029845B4 (de) Verfahren zur Diagnose von rheumatischen Erkrankungen
EP0021152B1 (fr) Procédé pour la détermination immunologique d'une matière de membrane basale, fragments de membranes basales spécifiques pour ce procédé et procédé pour leur préparation, resp. leur obtention
DE69429192T3 (de) Ein verfahren zur bestimmung von kollagenfragmenten in körperflüssigkeiten, ein testkit und mittel zur durchführung des verfahrens, und seine verwendung zur feststellung von mit dem kollagenmetabolismus assoziierten störungen
WO1998003872A2 (fr) Procede immunologique de mise en evidence d'anticorps diriges contre la transglutaminase tissulaire (ttg), utilisation de la ttg a des fins de diagnostic et de controle de therapie et agent pharmaceutique oral contenant de la ttg
Primakoff et al. Purification of the guinea pig sperm PH-20 antigen and detection of a site-specific endoproteolytic activity in sperm preparations that cleaves PH-20 into two disulfide-linked fragments
DE69333076T2 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
McDevitt et al. Experimental osteoarthritic articular cartilage is enriched in guanidine-soluble type VI collagen
Gill et al. Isolation and characterization of salivary antigens from Hyalomma anatolicum anatolicum
Kawaguchi et al. Involvement of Sacrophaga lectin in the development of imaginal discs of Sarcophaga peregrina in an autocrine manner
Swann et al. The chemical composition of bovine vitreous-humour collagen fibres
Nelson et al. Participation of calmodulin in immunoglobulin capping.
Larsson et al. Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis.
WO1992002558A1 (fr) Procede de purification de la cytokeratine 20 et son utilisation pour produire des anticorps
DE3425186A1 (de) Humanproteine, verfahren zu deren herstellung und diese enthaltende testkits
DE69727582T2 (de) Test zur quantifizierung von arthritiszustanden
DE69535173T2 (de) Allergieauslösende Proteine aus natürlichem Gummi-Latex, ihre Herstellung und Anwendung in Nachweismethoden
WO1989000164A1 (fr) Proteines membranaires specifiques des chondroblastes et procede de diagnostic et de controle de reactions auto-immunitaires contre des chondroblastes
CH668838A5 (de) Verfahren zum ermitteln von malignen tumorzellen mit metastatischer zellaktivitaet.
DE60035267T2 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
Shashoua Monomeric and polymeric forms of ependymin: a brain extracellular glycoprotein implicated in memory consolidation processes
Fife et al. Cartilage matrix glycoprotein is present in serum in experimental canine osteoarthritis.
DE3743402A1 (de) Neue monoklonale antikoerper und deren verwendung
EP0363449B1 (fr) Procede de recherche d'anticorps specifiques contre les maladies rhumatismales, en particulier la polyarthrite chronique, ainsi que reactif approprie
Petralanda et al. Pathogenesis of onchocercal dermatitis: possible role of parasite proteases and autoantibodies to extracellular matrix proteins
Frankel et al. Identification of locally synthesized proteins in proximal stump axons of the neurotomized hypoglossal nerve

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE